SRTS Stock Analysis: Buy, Sell, or Hold?
SRTS - Sensus Healthcare, Inc
$3.07
0.04 (1.32%)
▲
5d:
+4.07%
30d:
+8.1%
90d:
-26.9%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When SRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SRTS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SRTS shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SRTS is currently trading at $3.07, which is considered extended relative to its 30-day fair value range of $2.72 to $3.05. From a valuation perspective, the stock is trading at a discount (Forward PE: -183.8) compared to its historical average (204.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRTS is in a strong downtrend. Immediate support is located at $2.66, while resistance sits at $3.32.
Market Sentiment: SRTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.75 (+87.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SRTS is in a strong downtrend. Immediate support is located at $2.66, while resistance sits at $3.32.
Market Sentiment: SRTS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.75 (+87.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.72 -
$3.05
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 87.3% below Wall St target ($5.75)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.72 -
$3.05
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.66
Resistance Level
$3.32
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-183.83
Wall Street Target
$5.75
(+87.3%)
Revenue Growth (YoY)
-59.3%
Earnings Growth (YoY)
433.3%
Profit Margin
-34.5%
PE vs Historical
-183.8 vs 204.1
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 9:41 PM ET
Data refreshes hourly during market hours. Next update: 10:41 PM
Data refreshes hourly during market hours. Next update: 10:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRTS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Eric Sachetta
BUY
2000 shares
2026-02-24
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
Advanced SRTS Option Strategies
Professional options setups generated by AI based on today's SRTS price and gamma walls.
